Cargando…
Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
OBJECTIVES: To report the safety and immunogenicity profile of a protein subunit vaccine (MVC-COV1901) compared to AZD1222 and mRNA-1273 when given as a third (booster) dose to individuals who have completed different primary vaccine regimens. METHODS: Individuals were classified according to their...
Autores principales: | Estephan, Lila, Lin, Ying-Chin, Lin, Yi-Tsung, Chen, Yen-Hsu, Pan, Sung-Ching, Hsieh, Szu-Min, Torkehagen, Paal Fure, Weng, Yi-Jen, Cheng, Hao-Yuan, Estrada, Josue Antonio, Waits, Alexander, Chen, Charles, Lien, Chia En |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090360/ https://www.ncbi.nlm.nih.gov/pubmed/37080829 http://dx.doi.org/10.1016/j.vaccine.2023.04.029 |
Ejemplares similares
-
Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022) -
Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023) -
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022) -
A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022) -
Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)